Tag Directory / PFIZER showing 1–2 of 2

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera / MedCity

Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer prevails in $10B bidding war for Metsera

4 months / beckershospitalreview / Ella Jeffries

Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firm

4 months / endpoints / Kyle LaHucik

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera

4 months / medcitynews / Frank Vinluan

Novo Nordisk, Pfizer make personnel waves as they squabble over Metsera

4 months / endpoints / Alex Hoffman

Monday, November 10, 2025, 12:21 am / permalink 15823 / 4 stories in 4 months

Pfizer poised to buy Metsera in $10 bn deal after bidding war / Medical Express

medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #pfizer #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Pfizer poised to buy Metsera in $10 bn deal after bidding war

4 months / medicalxpress

Novo Nordisk raises Metsera bid again, hoping to top Pfizer's latest offer

4 months / endpoints / Drew Armstrong

Saturday, November 8, 2025, 3:21 pm / permalink 15805 / 2 stories in 4 months

PFIZER Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.

More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...

FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...

CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...

Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...

City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...